Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Shiwei Tablets (CST), also known by the Chinese name Fufang Shiwei Pian, is a traditional Chinese medicine (TCM) formulation developed and manufactured by Chengde Jingfukang Pharmaceutical Group. The drug is primarily indicated for the treatment of upper and lower urinary tract infections (UTI), specifically addressing pyretic stranguria of the dampness-heat Lower-jiao type as defined in TCM. The formulation is a compound herbal product where *Pyrrosia* (Shiwei) serves as a key active ingredient. Clinical studies have demonstrated that CST has therapeutic efficacy for UTIs and maintains a safe profile for clinical application. It is administered orally in tablet form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Shiwei Tablets.